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Transforming growth factors (TGFs) are polypeptides that have in certain
nontumorigenic cells an ability to reversibly induce features that resemble those
of malignant transformation (1, 2). There are two distinct types of TGFs, TGF-
a and TGF-0 (2, 3). TGF-a is related to epidermal growth factor (EGF) and
shares the same cell surface receptors, while TGF-# is structurally and antigeni-
cally distinct (1, 2). TGF-/3 has been molecularly cloned (4). It is a homodimer
with two disulfide-linked polypeptide chains of 12.5 kD (1, 4). Cell surface
receptors for TGF-,# are not related to the receptors of other known growth
factors and are widely distributed in different cells and tissues (2, 5, 6).
TGF-0 is present in a variety of cells including T cells, monocytes, and platelets
(2, 7-9). TGF-a also is known to stimulate production of fibronectin and collagen
by dermal fibroblasts in vitro (8, 10, 11). Roberts and coworkers (8) reported
that the subcutaneous injection of TGF-0 in newborn mice induced a rapid
fibrosis and accumulation of fibroblasts. This observation suggested to us that a
function of TGF-0 might be to induce fibroblast chemotaxis. In this report we
have observed that platelet-derived human TGF-/3 is a potent chemoattractant
for fibroblasts in vitro.
Materials and Methods
TGF-0 andEGF.
￿
TGF-0 was purified from homogenates of outdated human platelets
by procedures developed in our laboratory and previously published in detail (1, 5, 7).
The preparations for TGF-0 used in this study were tested for purity by polypeptide
analysis using silver staining of SDS polyacrylamide gels (1). All preparations used
contained only a 25-kD protein band on the gels which, after reduction with 2-ME,
migrated as a single 12.5-kD band and were active at ng/ml concentrations in a soft agar
colony formation assay using AKR-2B cells and growth inhibition assays using A549
indicator cells (1, 3). Antibodies were raised in rabbits to one of these preparations of
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TGF-0 and specifically blocked the binding of TGF-0 to its receptor on AKR-2B cells.
EGF was purified from male mouse submaxillary glands (5).
Preparation ofAnti-TGF-(3 Antibodies.
￿
Antibodies against homogeneously pure TGF-0
were raised in rabbits, and the IgG fraction was purified using a protein A-Sepharose
column (Keski-Oja, J., R. M . Lyons, and H . L. Moses, manuscript in preparation). Normal
rabbit IgG was purified in a similar manner to be used as a control .
Fibroblast Chemotaxis. Fibroblast chemotaxis was measured in modified blind-well
chemotaxis chambers equipped with porous (8 um) gelatin-treated polycarbonate filters
as previously described (12) . All samples were tested in triplicate or quadruplicate, and
where indicated activity was expressed as the mean number of fibroblasts per 200:1
immersion fields (01F) ± SEM of the replicates.
Other Fibroblast Chemoattractants.
￿
Human plasma fibronectin, heat denatured type I
calf skin collagen, and human platelet-derived growth factor (PDGF) were prepared as
previously described (12-14).
Incubation ofFibroblast Chemoattractants with Anti-TGF-/3 Antibodies.
￿
Purified IgG from
control and TGF-0-immunized rabbits (14 and 140 wg/ml) were added (10 Pl) to separate
200-Al aliquots of PBS (Grand Island Biological Co., Grand Island, NY) containing
fibronectin (600 ng), denatured type I collagen (6 mg), TGF-0 (3 pg), and PDGF (0 .3 pg) .
All of the samples were incubated at 37' for 2 h with frequent mixing. Volumes were
adjusted to 600 jul by addition of 390 wl serum-free Eagle's MEM (Grand Island Biological
Co.) and were tested in triplicate for fibroblast chemotactic activity.
Reduction ofTGF-0 by 2-ME.
￿
Two equal aliquots (1 .98 ml) of TGF-0 (500 ng/ml) were
prepared, 2-ME (20 tel) was added to one aliquot while PBS (20 ,1) was added to the other.
Both TGF-0 preparations were then kept at room temperature for 4 h. After extensive
dialysis at 4° C against PBS, the preparations were tested for their chemotactic activity
using the same assay at different doses.
Results
Chemotactic Property of TGF-/3.
￿
Purified human platelet-derived TGF-0 stim-
ulated migration of fibroblasts in modified Boyden chemotaxis chambers (Fig.
1). The dose-response curve was found to be bell-shaped, with maximal migration
occurring at a concentration of 12.5 pg/ml in the experiment depicted in Fig. 1 .
This same general dose-response curve was repeatedly observed with different
preparations of TGF-a, with maximal migration always being observed at doses
ranging from 5-50 pg/ml (data not shown).
Zigmond-Hirsch checkerboard analysis revealed that TGF-0 effected migration
of fibroblasts only when present in higher concentration in the lower compart-
tnent of the chemotaxis chambers (Table I), suggesting that it induces chemotac-
tic migration and not chemokinesis of fibroblasts (15).
Denaturation of TGF-0 by reduction of its disulfide bonds with 2-ME resulted
in a marked decrease in the ability of TGF-0 to act as a chemoattractant for
fibroblasts (e.g., chemotactic activity of TGF-,0, 5 pg/ml, was diminished from
54 ± 5 fibroblasts per 20 OIF to a value of 14 ± 3 after reduction by 2-ME
[migration to PBS control was 5 ± I]).
EGF has recently been shown (8, 16) to be capable of inhibiting TGF-0-
induced collagen synthesis by fibroblasts and to reverse TGF-(3-mediated growth
inhibition of A549 human lung carcinoma cells. In light of these observations,
we wanted to determine whether EGF might alter the chemotactic response of
fibroblasts to TGF-#. To address this issue, fibroblasts used in a chemotaxis assay
were incubated with different doses of EGF before and while they were present
in the upper compartment of chemotaxis chambers whose lower compartmentsPOSTLETHWAITE ET AL.
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FIGURE 1 .
￿
TGF-0 was tested in quadruplicate at the concentrations indicated for its ability
to induce fibroblast migration in modified blind-well chemotaxis chambers (see Materials and
Methods). The SE for each point on the graph were >15% of each mean value. Migration to
PBS control was 5 ± 1.
TABLE I
Effect of Varying Concentration Gradients of TGF-0on Fibroblast
Migration
Different concentrations of TGF-,B were added to the upper and lower compartments ofthe
chemotaxis chamber and the number of fibroblasts migrating to the lower surface of each
filter was quantitated. Each value represents the mean of four replicates ± SEM. The values
between the parallel lines were obtained when TGF-0 was present in a given chemotaxis
chamber at the same concentration in the uppr and lower compartments.
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contained TGF-0 or denatured type I collagen. EGFdid notalter the chemotactic
response of fibroblasts to either chemoattractant (Table II). These results indicate
that the chemotactic responsiveness of fibroblasts to TGF-0 is probably not
modulated by EGF.
Inhibition of TGF-/3-induced Chemotaxis by Anti-TGF-a Antibodies.
￿
Specific anti- If
antibodies have been shown by others (8) to inhibit TGF-,Q-induced
stimulation of collagen production by fibroblasts. To determine whether the
chemotactic activity of TGF-0 was susceptible to inhibition by specific anti-TGF-
0 antibodies, TGF-0 and other chemoattractants were incubated with IgG from
a rabbit immunized with TGF-0 (Table III). Normal rabbit IgG served as a
control. Anti-TGF-0 antibodies totally inhibited the ability of TGF-0 to act as a
TGF-0 Fibroblasts per 20 OIF at TGF-,6 concentration (pg/ml) in lower
concentration
in upper
compartment 50.0 25.0
compartment of:
12 .5 6.3 0
p8/ml
50.0 8±1 7±1 5±1 5±1 6±1
25.0 20±2 8t1 7±1 6±1 5±1
12.5 24±2 16±2 8±1 6±1 5±1
6.3 38±3 26±2 18±1 5±1 5±1
0 52±9 42±3 2713 17 t1 5±1254 POSTLETHWAITE ET AL.
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TABLE II
Chemotactic Response ofEGF-treated Fibroblasts to TGF and
Denatured Collagen
Condition*
Fibroblast per 20 OIF with lower compartment
Discussion
Different concentrations of EGF were preincubated with fibroblasts for 30 min at
37'C before they were added to prepared chemotaxis chambers containing either
TGF ordenaturetype I calfskin collagen. The EGF was present with the fibroblasts
in the upper compartments of the chemotaxis chambers during their incubation
in the chemotaxis assay. The values represent the mean of four replicates ± SEM.
* p values are not significant.
TABLE III
Inhibition of TGF-,Q-induced Chemotaxis by Anti-TGF-,Q Antibodies
Chemotactic
activity of
fibroblasts
per 20 OIF
P values*
* Chemoattractants were incubated with anti-TGF-0 or control IgG as described in
Materials and Methods.
Chemotactic values obtained with treatment of each chemoattractant with anti-
TGF-0 or IgG were compared with values for that chemoattractant treated with
PBS and analyzed by Student's t test.
fibroblast chemoattractant but did not inhibit the chemotactic activity of human
plasma fibronectin, human PDGF, or denatured type I calf skin collagen (Table
III) .
TGF-# purified from human platelets is a very potent chemoattractant for
fibroblasts in vitro. Dissociation by reduction of chains of TGF-# causes a marked
loss of its chemotactic potency, suggesting that the native structure of TGF-a is
essential for its ability to induce fibroblast chemotaxis. Polyvalent antibodies
raised in rabbits effectively block the chemotactic activity of TGF-,0. These same
TGF-# + PBS 88±6
TGF-# + anti-TGF-0 (140 ug/ml) 9 ± 1 <0.0025
TGF-fl + anti-TGF-# (14 ug/ml) 9 ± 1 <0.0025
TGF-,6 + IgG (140 ug/ml) 83 ± 8 NS
TGF-0 + IgG (14 jig/ml) 88 ± 7 NS
Denatured collagen + PBS 70±3
Denatured collagen + anti-TGF-0 (140 ug/ml) 70 ± 6 NS
Denatured collagen + anti-TGF-l3 (14 ug/ml) 71 ± 7 NS
Fibronectin + PBS 91±4
Fibronectin + anti-TGF-B (140 ug/ml) 90±6 NS
Fibronectin + anti-TGF-0 (14 tag/ml) 92 ± 8 NS
PDGF + PBS 76±6
PDGF + anti-TGF-0 (140 ug/ml) 78 ± 7 NS
PDGF + anti-TGF-Q (14 ug/ml 75±9 NS
PBS 12±1
EGF concentrations in
upper compartment
ng/ml
contents
TGF (5 pg/ml)
of.
Denatured type I
collagen (10 mg/ml)
50.0 55 ± 4* 33 t 2*
5.00 58±5* 37±2*
0.50 54 ± 6* 35 t 4*
0.05 47 ± 6* 32 t 3*
0 57±3 38±6POSTLETHWAITE ET AL.
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antibodies have been demonstrated to block the growth inhibitory effects of
TGF-# in fibroblasts (Keski-Oja, J., R. M. Lyons, and H. L. Moses, manuscript
in preparation) and is probably exerting its effect in this study by preventing
TGF-# from binding to receptors involved in the chemotactic response. The fact
that the anti-TGF-0 antibodies did not inhibit the chemotactic activity of PDGF,
fibronectin, or collagen further demonstrates specificity of the antibodies for
TGF-0.
A number of neoplastic and normal cells synthesize TGF-# (1, 2, 9, 11). The
fact that TGF-# is produced by a variety of cells and can modulate several
important fibroblast functions (i.e., chemotaxis, collagen, and fibronectin synthe-
sis) may have far-reaching implications. For example, certain tumors (e.g.,
schirrous carcinoma ofthe breast and stomach and fibrosarcomas) are character-
ized by an excessive fibrotic reaction which could be caused by their releasing
TGF-,0 (17). During embryogenesis, TGF-0 may play a critical role in directing
the migration of fibroblasts that synthesize the matrix scaffolding necessary for
organogenesis. The release of TGF-fl from platelets, lymphocytes, and mono-
cytes/macrophages at sites of immune and nonimmune tissue injury may play a
critical role in effecting the migration of neighboring connective tissue fibro-
blasts. It could then act as a stimulus for fibroblasts to produce increased
quantities ofmatrix components (collagens and fibronectin).
Summary
Transforming growth factor ,Q (TGF-f3) is a potent chemoattractant in vitro
for human dermal fibroblasts. Intact disulfide and perhaps the dimeric structure
ofTGF-a is essential for its ability to stimulate chemotactic migration of fibro-
blasts, since reduction with 2-ME results in a marked loss of its potency as a
chemoattractant. Although epidermal growth factor (EGF)appears to be capable
ofmodulating some effects ofTGF-(l, it does not alter the chemotactic response
of fibroblasts to TGF-,B. Specific polyvalent rabbit antibodies to homogenously
pure TGF-0 block its chemotactic activity but has no effect on the other
chemoattractants tested (platelet-derived growth factor, fibronectin, and dena-
tured type I Collagen). Since TGF-# is secreted by a variety of neoplastic and
normal cells including platelets, monocytes/macrophages, and lymphocytes, it
may play a critical role in vivo in embryogenesis, host response to tumors, and
the repair response that follows damage to tissues by immune and nonimmune
reactions.
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